Drug Trial Radar · NCT01332149
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
626
Actual
Start
Jul 2011
Primary completion
Apr 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy. This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.
Conditions
- Diabetic Neuropathy, Painful
Interventions
PregabalinDrug
Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn. At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.
Placebo matched with pregabalinDrug
Subject will take placebo matched with pregabalin twice a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline Mean Pain ScoreTime frame: Baseline
- Change From Baseline in Mean Pain Score at EndpointTime frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital affiliated to Capital Medical University, Neurology Department
Beijing, China
Peking University Third Hospital
Beijing, China
Endocrinology Department
Beijing, China
Beijing Hospital of the Ministry of Health
Beijing, China
Tongren Hospital Affiliated to Capital Medical University
Beijing, China
Chinese PLA General Hospital
Beijing, China
GuangZhou First Municipal People's Hospital
Guangzhou, China
Shanghai Changzheng Hospital
Shanghai, China
Huashan Hospital Affiliated Fudan University, Neurology Department
Shanghai, China
Shanghai Tenth People's Hospital/The Endocrinology Department
Shanghai, China
Shanghai First People's Hospital
Shanghai, China
Renji Hospital Shanghai Jiao Tong University School of Medicine/Neurology Department
Shanghai, China
Southwest hospital of the third military medical university/Department of Neurology
Chongqing, Chongqing Municipality, China
Fuzhou General Hospital of Nanjing Military Command
Fuzhou, Fujian, China
Department of Endocrinology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Dept. of Endocrinology, The first Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Dept. of Endocrinology, The second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Tongji Hospital,Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China
Xiangya Hospital of Centre-south University
Changsha, Hunan, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Dept. of Endocrinology, The second hospital of Jilin University
Changchun, Jilin, China
Shengjing hospital of china medical university
Shenyang, Liaoning, China
Qilu Hospital of Shandong University/department of internal neurology
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, School of medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.